Hanna Irie

Title: Hanna Irie: Innovator in Protein Tyrosine Kinase Research

Introduction

Hanna Irie is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of biomedical research, particularly in the area of protein tyrosine kinases. Her work focuses on developing innovative compounds and methods that can potentially transform the treatment of diseases related to PTK6.

Latest Patents

Hanna Irie holds a patent for "Protein tyrosine kinase 6 (PTK6) degradation/disruption compounds and methods of use." This patent discloses compounds that include a PTK6 ligand, a degradation/disruption tag, and a linker. The methods outlined in her patent aim to utilize these compounds in the treatment of PTK6-mediated diseases. She has 1 patent to her name, showcasing her innovative approach to addressing complex medical challenges.

Career Highlights

Hanna Irie is affiliated with the Icahn School of Medicine at Mount Sinai, where she conducts her research. Her work is characterized by a commitment to advancing scientific knowledge and improving therapeutic strategies. She has established herself as a key figure in her field, contributing to both academic and practical advancements in medicine.

Collaborations

Hanna collaborates with Jian Jin, a fellow researcher, to further explore the implications of her findings. Their partnership exemplifies the collaborative spirit that drives innovation in scientific research.

Conclusion

Hanna Irie's contributions to the field of protein tyrosine kinase research highlight her role as an innovative inventor. Her patent on PTK6 degradation/disruption compounds represents a significant step forward in the treatment of related diseases. Through her work at the Icahn School of Medicine at Mount Sinai, she continues to push the boundaries of biomedical research.